Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 4 December 2025 - 8 December 2025

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

As Wall Street gears up for the opening bell on Monday, December 8, 2025, Merck & Co., Inc. (NYSE: MRK) enters the week at a pivotal moment. The Dow component has rallied hard in recent months, but now faces a mix of powerful growth catalysts and fresh legal and financing questions that could shape the next leg of its move. On Friday, December 5, Merck shares slipped 1.16% to $99.72, marking a second straight daily loss and modest underperformance versus the broader market. The stock is still only about 6% below its 52‑week high of $105.84, set on November 25,
8 December 2025
····
Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

As Wall Street heads into Monday’s session, Eli Lilly and Company (NYSE: LLY) sits at the center of several big storylines: Chinese market access for its Alzheimer’s drug, a fresh FDA decision and new data for cancer therapy Jaypirca, price cuts for blockbuster obesity drug Zepbound, and a wave of institutional positioning. Below is a structured look at what matters for Eli Lilly stock before the U.S. market opens on Monday, December 8, 2025. 1. Where LLY Stock Stands After a Choppy Week In short, LLY heads into Monday as a mega‑cap growth stock that has cooled slightly but still
7 December 2025
·····
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Updated: December 7, 2025 – For informational purposes only, not investment advice. 1. VRTX stock snapshot as of early December 2025 Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy—and volatile—2025. As of the close on Friday, December 5, 2025, VRTX shares finished around $455.48, giving the company a market value in the $115–117 billion range.Stock Titan+3MacroTrends+3StockInvest+3 Key numbers investors are watching right now: Technically, several short‑term models still classify VRTX as a “buy or hold candidate”: StockInvest.us, for example, highlights a strong short‑term uptrend, with the price up almost 8% over the past two weeks and an estimated 3‑month target
7 December 2025
···
Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Updated: December 7, 2025 Merck & Co., Inc. (NYSE: MRK) — the U.S. pharmaceutical company behind blockbuster cancer drug Keytruda and HPV vaccine Gardasil — has just wrapped up a busy early-December news cycle. The company closed a multi‑billion‑dollar debt offering, secured fresh regulatory wins in its cardiopulmonary and animal-health franchises, boosted its dividend, and simultaneously ran into a new patent roadblock for its subcutaneous Keytruda injection in Germany. PR Newswire+4Wikipedia+4Stock Titan+4 Against that backdrop, MRK stock is trading near the top of its 52‑week range, and Wall Street is sharpening its forecasts for 2026 and beyond. MRK stock price
7 December 2025
·····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no wrong” growth icon to a complex mix of structural strengths (dominant GLP‑1 franchise, deep pipeline, global reach) and cyclical headaches (pricing pressure, competition, R&D setbacks). The Alzheimer’s shock: EVOKE and EVOKE+ miss their goal The biggest single blow of 2025
7 December 2025
·····
Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly (LLY) Stock on 6 December 2025: Zepbound Price Cuts, $1 Trillion Milestone and 2026 Forecasts

Eli Lilly and Company (NYSE: LLY) heads into the final weeks of 2025 as one of the most closely watched stocks on Wall Street – and not just in healthcare. After briefly crossing the $1 trillion market-cap mark in November on the back of explosive demand for its obesity and diabetes drugs, the stock has pulled back slightly but remains near record highs. Reuters+1 As of December 6, 2025, LLY is trading around $1,010 per share, giving it a market value just under the trillion‑dollar level and leaving investors debating whether the latest volatility is a buying opportunity or a
6 December 2025
····
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Published: December 6, 2025 – For information only, not investment advice. Johnson & Johnson stock (NYSE: JNJ) is ending the first week of December 2025 just below record territory after a powerful year-long rally, driven by a string of earnings beats, major acquisitions in neuroscience and oncology, and fresh clinical data in bladder cancer. At the same time, the company is absorbing huge jury verdicts in talc litigation and preparing to spin off its orthopaedics business, setting up a very different J&J for the second half of the decade. Reuters+4Johnson & Johnson Investor Relations+4Johnson & Johnson Investor Relations+4 Below is
6 December 2025
····
Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences Stock (GILD) Outlook 2026: Latest News, Trodelvy Data, Dividend and Analyst Forecasts

Gilead Sciences stock (NASDAQ: GILD) is trading near the upper end of its 52‑week range as of early December 2025, supported by stronger guidance, big HIV and liver franchises, and a mixed but important year for its oncology pipeline. At the same time, new deals in cell therapy and targeted protein degradation show management leaning into long‑term cancer bets, even at the cost of a bit of near‑term EPS. Here’s a detailed look at the latest price action, earnings, drug news, analyst forecasts and key risks that matter for GILD into 2026. Gilead Sciences stock price and recent trading As
6 December 2025
·····
Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Eli Lilly (LLY) Stock Outlook: Can the Obesity-Drug Giant Keep Justifying a $1,000 Share Price?

Updated: December 5, 2025 Eli Lilly and Company (NYSE: LLY) remains one of the most closely watched stocks in global markets as investors weigh eye‑popping growth in obesity and diabetes drugs against equally eye‑popping valuations and rising political pressure on drug prices. On December 5, 2025, Lilly shares are trading just above the $1,000 mark after recently touching an historic $1 trillion market capitalization, the first time a healthcare company has reached that milestone.CoinCentral At the same time, the company is cutting prices on flagship obesity drug Zepbound, navigating new U.S. “most‑favored‑nation” pricing rules, and preparing to ask regulators for
5 December 2025
·····
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally

GSK share price today, latest news, dividend, buyback activity and stock forecast as of 5 December 2025. GSK Share Price: Trading Near Multi‑Year Highs After a Strong 2025 GSK plc (LON:GSK; NYSE:GSK) is heading into year‑end 2025 on the front foot. As of the latest close before 5 December 2025, GSK’s London‑listed shares were trading around 1,826–1,837p, while the NYSE‑listed ADR ended at about $48.57 on 4 December.Investing.com+2Shares Magazine+2 That puts the stock close to its 52‑week highs of roughly $48.7 for the ADR and just below recent peaks in London, after a powerful run from roughly $34 per ADR
5 December 2025
······
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Updated: December 4, 2025 Amgen Inc. (NASDAQ: AMGN) has quietly turned into one of 2025’s standout large‑cap healthcare winners. The biotech heavyweight is trading just below fresh 52‑week highs, powered by a clean sweep of earnings beats, a deepening obesity‑drug story around its MariTide program, and full FDA approval for its lung‑cancer therapy Imdelltra. At the same time, investors are grappling with tax and patent overhangs, looming drug price pressure and an increasingly crowded obesity market. Here’s a deep, Google‑News‑friendly dive into the latest Amgen stock news, forecasts and analysis as of December 4, 2025. Amgen stock today: price, performance
4 December 2025
····
Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Regeneron (REGN) Price Target Hits $1,057 as BMO and Canaccord Lift Forecasts on Dupixent Growth

Published: December 4, 2025 Key Takeaways Wall Street Re‑rates Regeneron After Big Run — and Bigger Dupixent Story Regeneron Pharmaceuticals has suddenly become one of the most hotly debated large‑cap biotechs on Wall Street. On Thursday, December 4, 2025, multiple analyst moves and fresh data reshaped the Regeneron (REGN) stock narrative: Taken together, these moves signal that, despite a sharp rally off the summer lows, many professionals still see upside in REGN stock, driven primarily by Dupixent, Regeneron’s blockbuster anti‑inflammatory drug co‑developed with Sanofi, and a deepening pipeline in genetics and oncology. Investing.com+1 At the same time, concerns about valuation
4 December 2025
·····
1 … 40 41 42 43 44 … 56

Stock Market Today

Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Go toTop